Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225924 | 1.00 | CTNNB1 (0.38) | CTNNB1TCF7L2NR1H4BACE1FFAR1 | |
| SCHEMBL226599 | 0.94 | BACE1 (0.36) | CTNNB1TCF7L2BACE1S1PR1EPHX2 | |
| SCHEMBL226600 | 0.94 | BACE1 (0.36) | CTNNB1TCF7L2BACE1S1PR1EPHX2 | |
| SCHEMBL226703 | 0.92 | CTNNB1 (0.35) | CTNNB1TCF7L2BACE1FFAR1S1PR1 | |
| SCHEMBL226702 | 0.92 | CTNNB1 (0.35) | CTNNB1TCF7L2BACE1FFAR1S1PR1 | |
| SCHEMBL4494092 | 0.91 | CTNNB1 (0.42) | CTNNB1TCF7L2BACE1S1PR1LMNA | |
| SCHEMBL223529 | 0.87 | BACE1 (0.41) | NR1H4BACE1FFAR1FFAR4 | |
| SCHEMBL223530 | 0.87 | BACE1 (0.41) | NR1H4BACE1FFAR1FFAR4 | |
| SCHEMBL225346 | 0.85 | BACE1 (0.42) | NR1H4BACE1FFAR1FFAR4 | |
| SCHEMBL225345 | 0.85 | BACE1 (0.42) | NR1H4BACE1FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128409-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20120004202-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-7858616-B2 | Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090197876-A1 | INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-7547703-B2 | Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-06-16 | — | — | US | disclosed |
| EP-1835907-B1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-7169936-B2 | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20070004757-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ROTH GERALD J | 2007-01-04 | — | — | US | disclosed |
| US-20060148883-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| US-20050043389-A1 | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148883-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | COL1A1, MMP1, FOXM1 | CTNNB1 1378/4885TCF7L2 2979/4885NR1H4 97/4885 |
| US-20070004757-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | KDR, FLT1, EGFR | CTNNB1 908/4885TCF7L2 2678/4885NR1H4 563/4885 |
| US-20050043389-A1 | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | KDR, FLT1, EGFR | CTNNB1 908/4885TCF7L2 2678/4885NR1H4 563/4885 |
| US-20140128409-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | COL1A1, MMP1, FOXM1 | CTNNB1 1378/4885TCF7L2 2979/4885NR1H4 97/4885 |
| US-20120004202-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | COL1A1, MMP1, FOXM1 | CTNNB1 1378/4885TCF7L2 2979/4885NR1H4 97/4885 |
| US-20090197876-A1 | INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | KDR, FLT1, ERBB2 | CTNNB1 824/4885TCF7L2 2940/4885NR1H4 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.